Results 131 to 140 of about 6,658 (202)

Subcellular Redistribution of Endomembrane GPR15 Promotes NAD+-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. [PDF]

Cancer Res
Yue Z, Dai W, Cao Z, Hu B, Wang Z, Ma X, Qin D, Zhang T, Sang Q, Mei J, Yu T, Zhou Y, Luo Z, Xu J, Yuan Z, Li YY, Zhang J, Huang C, Yang Z.   +18 more
europepmc   +1 more source

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cancers (Basel)
Gąsowska-Bodnar A, Gąsowska-Bajger B, Żołnierek A, Żołnierek J, Bodnar L.   +4 more
europepmc   +1 more source

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer. [PDF]

ESMO Open
González-Martín A, Ledermann JA, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.   +2 more
europepmc   +1 more source

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India. [PDF]

J Ovarian Res
Yeshala SK, Panda SS, Moharana L, Saju SV, Rathinam K, Raju SH, Sehrawat A, Sundriyal D, Phillip AO, Kinsely PA, Bhatia KP, Kayal S, Dubashi B, Cyriac SL, Natarajan S, Samantaray L, Mohanty SS, Sadangi S, Pradhan S, Rana A, Ganesan P.   +20 more
europepmc   +1 more source

BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). [PDF]

Cancer Res Commun
De Souza AL, Hadfield MJ, Lu S, Golijanin DJ, Wood R, Margolis J, Anderson K, Olszewski AJ, Holder SL, El-Deiry WS, Aggarwal RR, Mega AE, Carneiro BA.   +12 more
europepmc   +1 more source

Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor. [PDF]

Cell Rep Methods
Marks D, Garcia E, Kumar S, Tyson K, Koch C, Ivanov AP, Edel JB, Mirza HB, Flanagan W, Dunsby C, French PMW, McNeish IA.   +11 more
europepmc   +1 more source

DNA damage response pathway alterations in urothelial carcinoma: a road to precision oncology or a dead-end street? [PDF]

Oncologist
Guerrero Serrano P, Sotoca P, García A, Calvo JC, González-Merino C, de Quevedo CG, Subiela JD, Bueno C, Albarrán V, Molina A, Pérez-Valderrama B, Gajate P.   +11 more
europepmc   +1 more source

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. [PDF]

Signal Transduct Target Ther
Camps-Fajol C, Minguillón J, Surrallés J.   +2 more
europepmc   +1 more source

Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer. [PDF]

Cancer Manag Res
Zhang L, Qiao R, Chen M, Yang Z, Gong M, Yu R.   +5 more
europepmc   +1 more source

Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE. [PDF]

Cancers (Basel)
Massobrio R, Attianese D, Testi A, Pascotto M, Campigotto B, Garulli C, Pace L, Ricotti A, Fuso L, Ferrero A.   +9 more
europepmc   +1 more source